Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Ernexa Therapeutics Inc ERNA

Healthcare Biotechnology
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes... see more

Current News (NDAQ:ERNA)

Ernexa Therapeutics to Present at Oxford Global's Cell 2025

GlobeNewswire 11 hours ago

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

GlobeNewswire 1 day ago

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor "What This Means" Platform

GlobeNewswire 5 days ago

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

PR Newswire 13 days ago

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

GlobeNewswire October 1, 2025

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

GlobeNewswire September 29, 2025

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

GlobeNewswire September 17, 2025

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

GlobeNewswire September 10, 2025

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire September 3, 2025
View More News ››

Opinion & Analysis (NDAQ:ERNA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ERNA)

ERNA.....Getting Pumped for a financing

Fluff NR this a.m.....Co has no cash Trade accordingly....$2
Iseneschal - 13 days ago
View more Bullboard ››

G Mining Ventures Corp.

G Mining Ventures Corp.

G Mining Ventures Corp. is a Canada-based mining company. The Company is engaged in the acquisition, exploration and ...
View More »